Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EndoTAG-1 plus gemcitabine for advanced pancreatic adenocarcinoma
ISRCTN24531831Phase 2Completed
- Sponsor
- Medigene AG
- Start
- Sep 2005
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of EndoTAG-1 and gemcitabine in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Medigene AG. Primary endpoints: Median overall survival, Median time to progression and 3 more. Started Sep 2005; status: completed.
02
Drugs
EndoTAG-1gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ISRCTN24531831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN24531831.